⌘K
Loading ticker…
As of 2026-08-24, AnaptysBio, Inc. Common Stock (ANAB) has a 3-month relative strength percentile of 43 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 65. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.6%, relative volume 1.54×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ANAB is in a stage 2 uptrend, week 1. Currently in a 91-day base; basing ADR 6.2% (broad 6.5%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 0.0% / 7.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
ANAB is held by 28 ETFs as of May 2026. Top owner: SCHA at 0.02% weight, $5M notional. Top 3 carry $13M.
Held by 61 ETFs · $175M across latest filings · largest weight 3.72% (FFTY).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.02% | $5M | — |
| VTWO | 0.03% | $5M | — |
| VHTVanguard Health Care ETF | 0.01% | $2M | — |
| VFMO | 0.12% | $2M | −0.05 pp |
| CANC | 0.99% | $2M | — |
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.28% |
| $1M |
| −0.12 pp |
| VTWG | 0.06% | $950K | — |
| OMFS | 0.30% | $849K | +0.29 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $588K | — |
| ONEQ | 0.00% | $487K | — |
Showing 10 of 28 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ANAB Jan avg: 5.93% median: 3.98% win: 50% σ: 23.17% n: 4 2022-04-12 → 2026-07-31 | ANAB Feb avg: 4.54% median: 4.11% win: 75% σ: 9.71% n: 4 2022-04-12 → 2026-07-31 | ANAB Mar avg: -3.28% median: -5.52% win: 50% σ: 11.05% n: 4 2022-04-12 → 2026-07-31 | ANAB Apr avg: 7.01% median: 8.08% win: 60% σ: 12.32% n: 5 2022-04-12 → 2026-07-31 | ANAB May avg: -8.80% median: -8.26% win: 20% σ: 8.26% n: 5 2022-04-12 → 2026-07-31 | ANAB Jun avg: 7.84% median: 6.49% win: 80% σ: 8.00% n: 5 2022-04-12 → 2026-07-31 | ANAB Jul avg: 5.74% median: 3.15% win: 60% σ: 21.96% n: 5 2022-04-12 → 2026-07-31 | ANAB Aug avg: 0.72% median: 4.59% win: 50% σ: 12.90% n: 4 2022-04-12 → 2026-07-31 (current) | ANAB Sep avg: 9.92% median: 0.56% win: 50% σ: 28.79% n: 4 2022-04-12 → 2026-07-31 | ANAB Oct avg: -3.02% median: 1.95% win: 50% σ: 24.86% n: 4 2022-04-12 → 2026-07-31 | ANAB Nov avg: 2.93% median: 4.82% win: 50% σ: 14.02% n: 4 2022-04-12 → 2026-07-31 | ANAB Dec avg: 8.27% median: 14.28% win: 75% σ: 40.82% n: 4 2022-04-12 → 2026-07-31 |